Education
About Us
Working with TipRanks
Follow Us
Beam Therapeutics (BEAM)
NASDAQ:BEAM
BEAM Stock Chart & Stats
$29.02
-$0.69(-2.55%)
At close: 4:00 PM EST
$29.02
-$0.69(-2.55%)
Day’s Range― - ―
52-Week Range$13.53 - $36.44
Previous CloseN/A
Volume491.48K
Average Volume (3M)1.70M
Market Cap
$3.12B
Enterprise Value$2.86B
Total Cash (Recent Filing)$1.07B
Total Debt (Recent Filing)$151.42M
Price to Earnings (P/E)―
Beta2.09
Next Earnings
Mar 03, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding101,474,945
10 Day Avg. Volume1,859,668
30 Day Avg. Volume1,697,679
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)2.78
Price to Sales (P/S)32.14
P/FCF Ratio-5.73
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue51.27
Enterprise Value/Gross Profit-8.02
Enterprise Value/Ebitda-6.64
Forecast
1Y Price Target
$43.08Price Target Upside48.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet And PartnershipsAnalyst notes that proceeds from a recent pharmaceutical collaboration have strengthened the balance sheet, creating a multi-year cash runway that reduces dilution risk and supports continued pivotal development.
Clinical EfficacyAnalyst highlights robust clinical signals across programs, including durable, dose-dependent increases in target protein for the alpha-1 program and consistent hemoglobin correction in the sickle cell cohort, indicating potential for meaningful disease modification.
Manufacturing And ScalabilityOptimized manufacturing with a shortened vein-to-vein timeline and faster engraftment supports scalable supply and could provide a commercial advantage versus slower rivals.
Bears Say
Commercial Adoption RiskRequiring an ex vivo transplantation procedure may limit patient and provider uptake compared with emerging in vivo editors that avoid transplantation, constraining potential market penetration.
Development And Enrollment UncertaintyAdditional enrollment needs at the selected dose for the lead in vivo program increase development uncertainty, which could delay regulatory submission timing and raise costs.
Regulatory And Biomarker RiskDependence on biomarker-based accelerated approval creates material risk if biomarker improvements fail to translate into clear clinical benefit or broader regulatory acceptance.
Beam Therapeutics News
BEAM FAQ
What was Beam Therapeutics’s price range in the past 12 months?
Beam Therapeutics lowest stock price was $13.53 and its highest was $36.44 in the past 12 months.
What is Beam Therapeutics’s market cap?
Beam Therapeutics’s market cap is $3.12B.
When is Beam Therapeutics’s upcoming earnings report date?
Beam Therapeutics’s upcoming earnings report date is Mar 03, 2026 which is in 32 days.
How were Beam Therapeutics’s earnings last quarter?
Beam Therapeutics released its earnings results on Nov 04, 2025. The company reported -$1.1 earnings per share for the quarter, missing the consensus estimate of -$1.038 by -$0.062.
Is Beam Therapeutics overvalued?
According to Wall Street analysts Beam Therapeutics’s price is currently Undervalued.
Does Beam Therapeutics pay dividends?
Beam Therapeutics pays a Quarterly dividend of $0.225 which represents an annual dividend yield of N/A. See more information on Beam Therapeutics dividends here
What is Beam Therapeutics’s EPS estimate?
Beam Therapeutics’s EPS estimate is -1.
How many shares outstanding does Beam Therapeutics have?
Beam Therapeutics has 101,474,945 shares outstanding.
What happened to Beam Therapeutics’s price movement after its last earnings report?
Beam Therapeutics reported an EPS of -$1.1 in its last earnings report, missing expectations of -$1.038. Following the earnings report the stock price went down -6.227%.
Which hedge fund is a major shareholder of Beam Therapeutics?
Currently, no hedge funds are holding shares in BEAM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beam Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.08 (48.45% Upside)
$43.08 (48.45% Upside)
Blogger Sentiment
Bullish
BEAM Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.88%
12-Months-Change
Fundamentals
Return on Equity
-47.19%
Trailing 12-Months
Asset Growth
11.93%
Trailing 12-Months
Company Description
Beam Therapeutics
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
BEAM Stock 12 Month Forecast
Average Price Target
$43.08
▲(48.45% Upside)
Technical Analysis
Denali Therapeutics
―
Immunovant
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Immunocore Holdings
―
Ownership Overview
Currently, No data available
---